GovChime
Notice ID: c7b47e26151e40f38804ba34321b7179Special Notice

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases

Active, responses due . Full description on SAM.gov.

Overview

Response deadline
5:00 PM EDT
Posted
September 30, 2024
Notice type
Special Notice
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NICHD
Place of performance
Bethesda, 20817
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
RFA-DK-23-017_RFA-DK-23-018
Notice ID
c7b47e26151e40f38804ba34321b7179

Description

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS) seeks industry collaborators to provide novel therapeutic agents, diagnostic markers, biomarkers and devices for use in NIH-sponsored multi-center clinical trials and ancillary studies in patients with childhood cholestatic liver diseases, including biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, and idiopathic neonatal hepatitis; and the liver disease related complications emanating from these diseases. BACKGROUND: The Childhood Liver Disease Research and Education Network (ChiLDReN) is a multi-center consortium of 10 clinical sites in the United States plus a scientific data coordinating center funded by NIDDK to study rare childhood liver diseases that result in cholestasis, including primary sclerosing cholangitis, biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, and idiopathic neonatal hepatitis. Five ongoing studies being conducted by ChiLDReN include: 1) A Prospective Database of Infants with Cholestasis (PROBE), a longitudinal observational study starting in infancy which has enrolled 890 infants with biliary atresia and 621 with intrahepatic cholestasis; 2) Biliary Atresia Study in Infants and Children (BASIC), a longitudinal study of children with biliary atresia both before and after liver transplant, which has enrolled over 1768 children with biliary atresia 3) Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC), a longitudinal study of intrahepatic cholestasis diseases, which has enrolled 474 subjects with Alagille syndrome, 572 with alpha-1 antitrypsin deficiency liver disease, 355 with PFIC and 36 with bile acid defects; 4) Longitudinal study of Mitochondrial Hepatopathies (MITOHEP) with 73 participants; and 5) Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH), a study of the prognostic value of hepatic ultrasound on the development of liver fibrosis in CF, which has enrolled over 770 subjects. In addition, ChiLDReN completed a placebo-controlled clinical trial to determine if post-operative corticosteroid therapy improves serum bilirubin and survival without liver transplantation in 140 infants with biliary atresia who have undergone the Kasai surgery ("START"). Ancillary studies to evaluate the natural history, clinical outcomes and quality of life, pathogenesis, genetics and genomics, proteomics, metabolomics, lipidomics, imaging studies, and determinants of progression and severity of these cholestatic liver diseases present a variety of research collaboration opportunities. ChilDReN is also interested in conducting clinical trials of promising therapies to improve clinical outcomes for these cholestatic liver diseases. Finally, improved diagnostics or screening procedures for biliary atresia and cholestasis in infants are of great interest to ChiLDReN. STUDY GOALS: The overall goal of ChiLDReN is to determine the etiology, genetics, pathogenesis, natural history, clinical outcomes, complications, predictors of outcomes and optimal therapy of the cholestatic liver diseases. ChiLDReN studies have enrolled and are following a relatively large and well characterized population of children and young adults with these rare disorders. ChiLDReN is interested in conducting research that will lead to improved clinical outcomes in children and young adults with these cholestatic liver diseases with industry collaborators to: • Evaluate the natural history, pathogenesis, diagnosis, genetic factors, genomics, proteomics, metabolomics, lipidomics, epigenomics, imaging studies, and determinants of progression and severity of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. • Explore use of serum markers for fibrosis and serum markers for disease activity to predict hepatic histology either by themselves or in combination with other clinical, laboratory, genomic, proteomic, metabolomic, and lipidomic variables • Explore the utility of these serum markers as surrogate markers of therapeutic response in study subjects participating in treatment trials (e.g., START study for biliary atresia) • Investigate proprietary drugs (such as novel choleretic agents, anti-fibrogenic agents, autophagy inducers, chloride channel inducers, fat-soluble vitamin supplements, bone mineral density agents, etc.), reagents, or devices in controlled randomized clinical trials as potential diagnostics or therapies for biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis • Evaluate novel newborn or infant screening techniques or devices for biliary atresia or cholestasis. • Evaluate noninvasive imaging methods for assessing fibrosis, biliary disease, and parenchymal pathology in these diseases including but not limited to the use of elastography, nuclear magnetic resonance imaging, and molecular imaging. • Evaluate the use of cytokine assays for analyses of serum/plasma cytokine levels as markers of disease activity and as surrogate markers of histologic or clinical improvement in therapeutic trials CAPABILITY STATEMENT: Commercial organizations interested in pursuing clinical collaborations with NIDDK for childhood cholestatic liver diseases are required to submit a Capability Statement to NIDDK. The Capability Statements submitted in response to this announcement will be used to evaluate and select industry collaborators. The Capability Statement should not exceed 10 (ten) pages of narrative (not including appendices) and should include the following information: 1. A description of the therapeutic, diagnostic or device proposed to be used in the clinical research study. (Note: The proposed therapeutic or device must have been tested already in a Phase I trial in humans.) 2. The specific details of the methods to be utilized in the investigation of the pharmacologic, surgical or device intervention in patients with biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis, and a clear description of all important issues surrounding the evaluation of disease progression in these patients. 3. A detailed plan demonstrating the ability to provide sufficient quantities of the therapeutic, diagnostic or device in a timely manner for the duration of the study. 4. A description of all laboratory tests that are needed, including assays and required amount of specimens, to determine specific biomarker levels along with appropriate methods for performing such tests. 5. A description of other core facilities and interactions with core facilities that are needed for the study. 6. Dosing and pharmacokinetic data from human studies for any novel therapeutics. 7. Adverse event profile for the proposed therapeutic or device. 8. A description of the practices and procedures that would be used to assure patient privacy and maintain confidentiality of data obtained from the study. 9. (Optional) Outcome measures of interest to the organization. The specifics of the proposed outcome measures should include but not be limited to treatment and evaluation of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. 10. Any other resources the organization proposes to commit to the collaboration (in addition to the proposed therapeutic, diagnostic or device), which may include any of the following: equipment, reagents, supplies, access to facilities, personnel or services, and, if appropriate, funding (pursuant to a Cooperative Research and Development Agreement (CRADA) authorized under 15 U.S.C. § 3710a), to help support the conduct of the clinical study. 11. Affirmative statements that the organization: a. agrees to provide a Letter of Cross Reference to the Drug, Biologic or Device Master File for the proposed therapeutic or device, which will be included with any US FDA filing by the IND or IDE Sponsor of the ChiLDReN study; b. agrees to have the proposed therapeutic, diagnostic or device used in ChiLDReN-developed protocols which will be conducted by the ChiLDReN research network for which the study data collection and analysis will be performed by the ChiLDReN Scientific and Data Coordinating Center; c. agrees to assure patient privacy and will maintain confidentiality of data obtained from the study; d. agrees to share all safety data from other studies involving the proposed therapeutic or device as well as relevant efficacy data from other studies (updated Investigator Brochure, etc) with the ChiLDReN; e. understands that because the ChiLDReN network is supported by NIDDK funding, the study results will be published and therefore agrees to the prompt publication of research results from the clinical study using the organization's proposed therapeutic, diagnostic or device; and f. understands that the clinical study will be conducted under an agreement with NIDDK which must adhere to PHS intellectual property policies (see: http://www.ott.nih.gov/policy/phspat_policy.aspx). SUBMISSION: Capability Statements received by NIDDK will be considered. Prospective collaborators may be invited to attend, at their own expense, a ChiLDReN Steering Committee meeting to be held in the Baltimore-Washington, DC area to discuss the information in their Capability Statement with the Steering Committee members. NOTE:NO FUNDS WILL BE PROVIDED BY NIDDK TO ANY ORGANIZATION SELECTED FOR THIS CLINICAL RESEARCH COLLABORATION OPPORTUNITY. SUBMISION AND INQUIRIES: Submit Capability Statements to: NOO Coordinator, National Institute of Diabetes and Digestive and Kidney Diseases e-mail: niddkottdip@niddk.nih.gov For Scientific Inquiries contact: Edward Doo, MD Director, Liver Diseases Research Program Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6149 Bethesda, MD 20892-5450 Telephone: (301) 451-4524 FAX: (301) 480-8300 e-mail: dooe@niddk.nih.gov Katrina Loh, MD Director, Pediatric Gastrointestinal and Liver Diseases Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6148 Bethesda, MD 20892-5450 Telephone: (301) 827-1079 FAX: (301) 480-8300 e-mail: katrina.loh@nih.gov For Inquiries Regarding Partnering with NIDDK (Intellectual Property Matters and Collaboration Agreements) contact: Agnes Rooke, JD Technology Advancement Office NIDDK, NIH, HHS Telephone: 301-451-6072 e-mail: Agnes.Rooke@nih.gov This Notice of Opportunity is also posted at: http://techdev.niddk.nih.gov/collabs.shtml.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

No documents available.

Lifecycle

  1. 1
    Version 1Special NoticeCurrent

    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases

    Notice c7b47e26151e40f38804ba34321b7179 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This is a Request for Information (RFI) for Research and Development (R&D) open to all interested organizations, regardless of business size. This is NOT a solicitation for capability statements, proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain industry input to inform requirements development and acquisition planning for the proposed research services described in the attached draft Statement of Work (SOW). The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). This RFI is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. Interested organizations are encouraged to review the attached draft SOW and respond to the information requests outlined in this notice. The Government anticipates issuing a solicitation for this requirement at a later date under a separate announcement. Issuance of this notice does not obligate the Government to issue a solicitation or award a contract.
54%
Special Notice11/17/2026
This is a Small Business Sources Sought (SBSS) Notice for Research & Development (R&D). This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of qualified small businesses under the size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the small business size standard for such requirements is 1,000 employees or less, including applicable affiliates. This SBSS notice is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The purpose of this synopsis is to identify small business organizations with requisite qualifications to provide the services stated herein. Based on capability statements received in response to this Sources Sought Announcement, this acquisition may be solicited as a small business set-aside. All small business organizations (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) are encouraged to respond to this notice. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice.
54%
Market Research11/19/2026
This is a Request for Information (RFI) for Research and Development (R&D) open to all interested organizations, regardless of business size. This is NOT a solicitation for capability statements, proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain industry input to inform requirements development and acquisition planning for the proposed research services described in the attached draft Statement of Work (SOW). The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). This RFI is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. Interested organizations are encouraged to review the attached draft SOW and respond to the information requests outlined in this notice. The Government anticipates issuing a solicitation for this requirement at a later date under a separate announcement. Issuance of this notice does not obligate the Government to issue a solicitation or award a contract.
53%
Special Notice11/17/2026
This is a Small Business Sources Sought (SBSS) Notice for Research and Development (R&D). This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of qualified small businesses under the size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the small business size standard for such requirements is 1,000 employees or less, including applicable affiliates. This SBSS notice is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The purpose of this synopsis is to identify small business organizations with requisite qualifications to provide the services stated herein. Based on capability statements received in response to this Sources Sought Announcement, this acquisition may be solicited as a small business set-aside. All small business organizations (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) are encouraged to respond to this notice. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice.
53%
Market Research11/23/2026
Request for Information Request for Information No. 75N94027R00005 Title NIMHD Division of Intramural Research Population Health and Clinical Research Type Research and Development (R&D) RFI Anticipated NAICS Code 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) Response Date 4:00PM (Eastern) Thursday, November 19, 2026 Primary Point of Contact Edwin Osorio, Contract Specialist — edwin.osorio@nih.gov Secondary Point of Contact Lisa Schaupp, Contracting Officer — lisa.schaupp@nih.gov Description This is a Request for Information (RFI) for Research and Development (R&D) open to all interested organizations, regardless of business size. This is NOT a solicitation for capability statements, proposals, proposal abstracts, or quotations. The purpose is to obtain industry input on the attached draft Statement of Work (SOW), the commercial availability of the contemplated services, customary industry practices, and alternative approaches to meeting the Government’s needs. This RFI is for market research and planning purposes only. The Government has not made a final determination regarding commerciality, acquisition strategy, task order pricing arrangements, or small business set-aside status. A solicitation may be issued later under a separate announcement; this RFI does not obligate the Government to issue a solicitation or award a contract. Related notice: Small Business Sources Sought No. 75N94027R00005, published November 10, 2026. This separate RFI seeks industry feedback on the draft SOW and commercial availability; formal capability statements are not required. This RFI does not amend the separate Sources Sought notice or its response instructions. Background and Project Requirements The National Institute on Minority Health and Health Disparities (NIMHD), Division of Intramural Research (DIR), within the National Institutes of Health (NIH), seeks input on R&D social and behavioral sciences research services supporting population health and clinical research to understand and reduce health disparities in the United States. The contemplated effort encompasses the development, conduct, coordination, monitoring, analysis, and completion of multiple research studies through an Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Study designs may include population-based cross-sectional surveys; epidemiological studies, including longitudinal cohort and case-control studies; clinical trials; community-based intervention studies; simulation modeling; and qualitative research, including observations, interviews, and focus groups. As described in the draft SOW, potential services include project management; research site and subcontract management; access to investigators, laboratories, facilities, equipment, and qualified personnel; participant recruitment and retention; community engagement; protocol development and implementation; regulatory and human-subjects protection support; site and safety monitoring; data collection, management, and statistical analysis; training; information security; and transition of research resources and data at contract completion. Individual task orders may differ in research design, populations, sites, duration, and complexity. For context, the related Sources Sought requested experience managing 3–6 studies annually, studies involving approximately 100–10,000 participants, and studies lasting from a few months to several years. These are experience ranges in that notice, not guaranteed task order quantities or established workload commitments. Respondents should identify assumptions affecting their feedback. Anticipated Award Date and Period of Performance The Government anticipates award of an IDIQ contract approximately in September 2027. Specific research activities and task order performance periods would be identified in individual task orders. Anticipated IDIQ ordering period Approximately five years Draft Statement of Work Feedback Provide comments or recommendations identifying the applicable SOW section or numbered item. Address unclear requirements, implementation challenges, opportunities to improve performance outcomes, and alternative or commercially available approaches. Identify requirements that may unnecessarily limit participation, including small business participation, and suggest practical revisions. Respondents may address all or selected portions of the draft SOW. Commercial Availability of Services The Government seeks evidence concerning whether the contemplated services, in whole or in part, are available in the commercial marketplace or could be met through customary commercial approaches. Please address the questions below to the extent relevant, distinguishing existing offerings from proposed study-specific development. Identify applicable SOW sections and provide nonproprietary supporting information where available. 1. Comparable commercial services. Which services or combinations of services described in the draft SOW are offered and sold to nongovernmental customers? Describe comparable tasks or outcomes, customer types, and similarities and differences in scope, scale, study complexity, and integration. Public descriptions, service literature, or nonproprietary examples may be provided; do not disclose confidential customer information. 2. Commercial sales and terms. For those services, describe whether and how they are offered and sold competitively, the frequency and extent of commercial sales, and customary commercial terms and conditions. Identify public sources or other nonproprietary information supporting the response. Distinguish experience serving Government customers from evidence of commercial-market sales. 3. Customary pricing practices. Describe customary pricing methods for specific tasks or outcomes, including established catalog or market prices where available, units of sale, and how prices can be substantiated. Identify typical payment arrangements and relevant commercial terms. Describe practices rather than submitting a binding quotation or a detailed cost proposal. 4. Customization and integration. Identify which SOW elements can be met through existing commercial services, which require customary tailoring, and which require specialized development or integration beyond customary practice. Explain the nature, extent, and principal cost or schedule drivers of any differences, including protocol-specific work, site coordination, data integration, security, or transition requirements. 5. Alternative approaches. Could the Government’s needs be met more effectively by restating requirements, using commercial service packages, or acquiring separable portions commercially? Describe feasible alternatives, dependencies, and potential effects on research continuity, oversight, performance, cost, schedule, and small business participation. 6. Pricing arrangements and research uncertainty. Identify portions suitable for firm-fixed-price arrangements and the conditions needed to define tasks, deliverables, outcomes, and acceptance criteria. For portions not suitable, explain the uncertainty or risk and describe customary alternative arrangements. Address differences across study designs, sizes, durations, and complexity. Respondents need not develop a technical proposal, identify a complete team, or submit formal past-performance information. Brief examples are requested only to substantiate market information and recommendations. General Information All interested organizations, regardless of business size, are encouraged to respond. Respondents may address the requirement in its entirety or in portions and should identify the areas addressed. Relevant experience or comparable-service examples may support the feedback; formal capability statements are not required. Responses must include the organization’s name, SAM.gov Unique Entity Identifier, physical address, and technical and administrative points of contact, including names, titles, telephone numbers, and email addresses. Identify business size status under the anticipated NAICS code and any applicable small business socioeconomic categories. Information Submission Instructions Submit responses electronically by email to Edwin Osorio, Contract Specialist, at edwin.osorio@nih.gov and Lisa Schaupp, Contracting Officer, at lisa.schaupp@nih.gov, in Microsoft Word or Adobe Portable Document Format (PDF). Responses are due November 19, 2026 (Thursday) - 4:00PM (Eastern) Reference on all correspondence 75N94027R00005 - RFI Organize responses by the headings and numbered questions in this RFI and identify the draft SOW section or item discussed. All information and questions must be submitted in writing to both points of contact. Organizations that responded to Sources Sought No. 75N94027R00005 may submit additional information focused on the questions in this RFI. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or pay for information submitted. No award will be made as a result of this RFI. Respondents are responsible for all costs of preparing and submitting responses. Responses are voluntary and are not offers. Participation in this RFI is not a prerequisite to responding to a future solicitation. The Government reserves the right to use nonproprietary information provided for acquisition planning, refinement of the requirement, and other legally appropriate purposes. The Government is under no obligation to acknowledge receipt or provide individualized feedback. A solicitation may be published separately in SAM.gov. Responses to this RFI will not constitute responses to any future solicitation. Any determination regarding commerciality, competition, or acquisition strategy will be made by the Government. Confidentiality Responses must not include proprietary, classified, confidential, or sensitive information. Provide public or nonproprietary supporting information only; do not include identifiable research-participant information. Attachment Draft SOW — NIMHD DIR IDIQ Population Health and Clinical Research, dated October 30, 2026
49%
Market Research11/25/2026

Additional Details

Solicitation Number

RFA-DK-23-017_RFA-DK-23-018

Archive Date

Jun 15, 2029

Office Address

BETHESDA, MD, 20817